(Q44942024)

7 December 2017

title

The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies (English)

1 reference

7 December 2017

0 references

0 references

Jyrki Lilleberg

1

1 reference

7 December 2017

Vesa Ylönen

series ordinal

2

1 reference

7 December 2017

Lasse Lehtonen

series ordinal

3

1 reference

7 December 2017

Lauri Toivonen

series ordinal

4

1 reference

7 December 2017

publication date

1 May 2004

1 reference

Scandinavian Cardiovascular Journal

7 December 2017

published in

1 reference

7 December 2017

volume

38

1 reference

7 December 2017

issue

2

1 reference

7 December 2017

page(s)

80-84

1 reference

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14017430410025783

The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14017430410025783

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14017430410025783

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14017430410025783

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14017430410025783

Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14017430410025783

Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14017430410025783

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14017430410025783

10.1080/14017430410025783

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference